Please use this identifier to cite or link to this item:
|Title:||Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009||Authors:||Poon, D.
Van Cutsem, E.
|Issue Date:||Nov-2009||Citation:||Poon, D., Anderson, B.O., Chen, L.-T., Tanaka, K., Lau, W.Y., Van Cutsem, E., Singh, H., Chow, W.C., Ooi, L.L., Chow, P., Khin, M.W., Koo, W.H. (2009-11). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10 (11) : 1111-1118. ScholarBank@NUS Repository. https://doi.org/10.1016/S1470-2045(09)70241-4||Abstract:||Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems. © 2009 Elsevier Ltd. All rights reserved.||Source Title:||The Lancet Oncology||URI:||http://scholarbank.nus.edu.sg/handle/10635/110434||ISSN:||14702045||DOI:||10.1016/S1470-2045(09)70241-4|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 12, 2020
WEB OF SCIENCETM
checked on Jul 10, 2019
checked on Feb 15, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.